NDATOPICALAEROSOL, FOAM
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZILXI (minocycline) by Journey Medical is 12. First approved in 2020.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZILXI is a topical foam formulation of minocycline, a tetracycline antibiotic, approved for acne vulgaris treatment. The mechanism of action remains unknown, though minocycline demonstrates in vitro activity against Propionibacterium acnes with low resistance propensity. Applied once daily to affected body areas, ZILXI achieves rapid steady-state pharmacokinetics with minimal systemic accumulation.
$0.403MPart D
Peak4.3 years to LOEProduct is at peak commercial maturity with modest Part D utilization; commercial team focus is on maintaining market position against high competitive pressure (score: 8/10).
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of AMZEEQ for the treatment of acne is unknown. 12.2 Pharmacodynamics The pharmacodynamics of AMZEEQ for the treatment of acne are unknown. 12.3 Pharmacokinetics In a pharmacokinetic study, male and female subjects 18 years of age or older with acne…
Indications
Worked on ZILXI at Journey Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.